TABLE 2.
Differences in respiratory function and exacerbations between patients with cystic fibrosis who had at least one sputum culture positive for Achromobacter xylosoxidans (Ax+) and cystic fibrosis patients uninfected by A. xylosoxidans (Ax−)
| Characteristics | Control subjects (n=36) | Patients (n=36) | p-value |
| Lung function | |||
| ΔFEV1 %·year−1 | −3.05±0.54 | −5.27±0.47 | 0.002# |
| ΔFEV1 mL·year−1 | −63.8±18.5 | −153.6±16.1 | <0.001# |
| ΔFVC %·year−1 | −2.42±0.86 | −3.58±0.56 | 0.18 |
| ΔFVC mL·year−1 | −101.0±32.1 | −160.0±21.0 | 0.06 |
| Exacerbations n | |||
| Year before baseline | 1.5 (0.0–5.0) | 2.0 (1.0–3.5) | 0.77¶ |
| Year after baseline | 0.5 (0.0–4.0) | 2.0 (1.0–4.0) | 0.16¶ |
| Years 1 and 2 after baseline+ | 5.0 (4.0–6.0) | 6.0 (4.0–8.0) | 0.034¶ |
| Years 1–3 after baseline + | 7.0 (5.0–10.0) | 9.0 (7.0–12.0) | 0.033¶ |
Data are presented as β±se (slope of change calculated from the baseline (time of bacterial detection)) or median (interquartile range), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. #: Calculated from the group×time interaction term of the linear mixed model;¶: calculated using a generalised linear mixed model (Poisson regression model) including matched sets as a random effect; +: cumulative number of exacerbations.